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ABSTRACT  
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Background 
Obesity can be associated with increased cardio-metabolic risk, but some subjects with obesity do 
not show metabolic impairment and escape this association. Low grade inflammation (i.e.,  high 
sensitivity C-reactive protein [hsCRP] >3 mg/dl) is associated with high cardiovascular risk in 
obesity.  We investigated  renin-angiotensin system (RAS) activity in cultured circulating T-cell in  
subjects with obesity with and without angiotensin II (Ang II)   stimulation in the presence or 
absence  of low-grade inflammation. 
Materials and methods 
We studied 18  subjects  with obesity and 10 healthy subjects.  After T-lymphocyte isolation, T- 
cells mRNAs for angiotensin converting enzyme (ACE) and AT1-receptor  were quantified by  
reverse transcription polymerase chain reaction   at baseline and after  Ang II  stimulation. hsCRP, 
plasma renin  and ACE activity in the cell pellet and supernatant  and Ang II T-cell content were 
also measured.  
Results 
T-cell RAS in subjects with obesity with low grade inflammation was more activated than in 
subjects with obesity  without low grade inflammation.  The increase in RAS activation occurred 
both at  baseline and after Ang II stimulation. Similarly the release of ACE activity in the 
supernatant was significantly higher in subjects with obesity  with hsCRP>3 mg/dl tha in subjects  
hsCRP<3 mg/dl and controls. 
Conclusions 
Circulating T-cell based RAS is activated in subjects with obesity  independently of low grade 
inflammation that amplifies the T-cell RAS response to Ang II stimulation.   
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INTRODUCTION  
        Obesity is a complex disease characterized by excessive expansion of adipose tissue and is an 
important risk factor for chronic diseases such as cardiovascular disorders, hypertension and type 
2 diabetes . 1  Accumulated evidence suggests that the renin-angiotensin system (RAS) strictly 
relates to inflammation, mitochondrial dysfunction  and oxidative stress as possible mechanisms 
linking RAS to obesity and insulin resistance. 2 
Obesity  is characterized by chronic low-grade systemic inflammation, which in part emanates 
from adipose tissue inflammation . This occurs when immune cells such as macrophages and T- 
cells infiltrate adipose tissues 3 and  secrete pro-inflammatory substances  including Angiotensin II 
(Ang II) ,that spill into the bloodstream and contribute to systemic inflammation.  
Adipose tissue has been considered recently as a distinct endocrine organ  that produces multiple 
bioactive mediators, known as adipokines that play a functional role in the regulation of 
metabolism, inflammation and tissue remodeling .4  Recent studies indicate that a functional RAS 
exists in the adipose tissue and is involved in the pathophysiology of metabolic disorders.5  
Adipose tissue RAS overactivation causes glucose intolerance and systemic insulin resistance. 6 
Accordingly both adipose-specific gene overexpression and knockout mouse models of  RAS 
components were investigated.7,8,9  Over-expression of  angiotensinogen (Agt) specifically in 
adipose tissue resulted in increased fat mass, fat cell size, adipose and systemic inflammation as 
well as insulin resistance. By contrast, inactivation of Agt in adipose tissue improved glucose 
clearance, reduced inflammation, adipose tissue macrophage infiltration and also enhanced 
metabolic activity .10,11,12  
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       The pathophysiological actions of Ang II are mediated by the angiotensin II type 1 receptor 
(AT1R). Therapeutic effects of  irbesartan,  an AT1R specific blocker, were  recently shown in 
genetically obese diabetic KKAy mice, a model of human metabolic disorders without any dietary 
loading, with  focus on the analysis of possible effects of irbesartan on  adipose tissue. The 
treatment with irbesartan significantly lowered systolic blood pressure with a concomitant 
decrease in body weight in KKAy mice .13 
       Human visceral adipose tissue is rich in lymphocytes; human T-lymphocytes have been  shown 
to express a functional RAS and to be able to synthesize Ang II.14,15      
       In  our  previous study we reported  that the hypertensive patients with low-grade 
inflammation and more marked T-cell RAS activation also had higher body mass index (BMI) and 
waist circumference values. 15 This study was aimed at investigating, whether a selective  
upregulation of  circulating lymphocyte-based RAS occurs in subjects with obesity and whether T-
cell RAS is  modulated differently  by Ang II in  subjects with obesity  with or without low-grade 
inflammation. 
 
 
METHODS 
Subjects 
       The protocol of this study complies with the principles of the Helsinki declaration. The study 
was approved by the internal review board and written, informed consent was obtained from 
each subject. 
        T-lymphocytes were obtained from 18 subjects with obesity, 43-67 years old,  all with BMI >30 
who attended  our out-patient  clinic.  No patient  was on treatment with angiotensin converting 
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enzyme (ACE) inhibitors, AT1 R antagonist or diuretics. Exclusion criteria were both primary and 
secondary forms of  arterial hypertension;  ischemic heart disease/acute coronary syndrome or 
stroke in the previous 6 months; left-ventricular (LV) ejection fraction <50%; diabetes mellitus; 
renal failure (creatinine clearance <60 ml/minute); presence of a major illness such as cancer, liver 
disease, chronic and acute inflammatory disease or infectious disease in the previous 3 months. 
These exclusion criteria can induce an activation of systemic and T-cell RAS. No subject was under 
treatment with anti-inflammatory drugs. Ten subjects without obesity were enrolled into the 
study as a control group and were comparable for age and sex to the group with obesity. 
The main demographic and clinical  characteristics of enrolled subjects are shown in Table 1. 
According  to high  sensitivity C-reactive protein (hsCRP) values at enrolment,  subjects with 
obeisty were divided into 2 groups according to hsCRP  value (>3 mg/l or < 3 mg/l).  Blood hsCRP 
level and other general chemical tests were carried out as  part of a routine medical check-up.  
Experimental procedures     
T-lymphocyte isolation 
         Venous  blood was drawn  from the antecubital vein, collected in a sterile flask containing  
3.8% sodium citrate (9/1, vol/vol)  and T-lymphocytes  isolation was carried out according to our 
previous report. 14 Magnetic beads conjugated  to  anti-human CD 3 (Miltenyi Biotec, Germany) 
were used for positive selection of  T-lymphocytes. In  each incubation experiment mRNA 
expression of ACE,  AT1R  and  interferon (IFN) gamma, ACE activity and Ang  II concentrations 
were studied in the cell pellet and in the supernatant.  
        To study the effect of stimulation by Ang II on  ACE and AT1R gene expression, ACE activity 
and Ang II concentrations, T- lymphocytes were cultured in a cell incubator (Forma Scientific) at 
37°C in a humidified atmosphere at 5% CO2 for 6, 18 and 24 hours with and without  0.05 nmol/L 
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Ang II addition to the culture medium. We used 0.05 nmol/L of Ang II  because this concentration 
is close to human Ang II plasma values. 
  
Real-Time PCR  for ACE gene expression and Reverse Transcriptase-Polymerase Chain Reaction  
analysis for AT1R and IFN-gamma gene expression 
       Isolation of total RNA was performed as described previously.14 FAM-labelled  probes and 
primers for ACE (ACE Hs00174179_m1, Applied Biosystems, Foster City, CA) and  for the 
housekeeping gene beta-actin (Invitrogen, Milan, Italy) were used.  Relative gene expression was 
calculated as 2 -Ct (Ct = Ct of the target gene minus Ct  of beta actin). mRNAs for AT1R  and  IFN 
gamma  were semi-quantified  versus the housekeeping  gene glyceraldeyde-3-phosphate 
dehydrogenase (GAPDH) by reverse transcriptase-polymerase chain reaction (RT-PCR)(Applied 
Biosystems) 14 using specific primers at annealing temperature and cycle number, as already 
reported.15  
Measurement of  serum adiponectin  
        Human total adiponectin was performed in serum by a commercial kit (R&D Systems, MN, 
USA).  
Measurement of ACE activity and  Ang II concentration in T-cells. 
       ACE activity measurement and Ang II concentration were performed as previously  
described.15  Ang II levels were expressed as fmol/mg of proteins. 
Measurement of plasma Ang II concentration 
       Plasma Ang II levels were measured by a chemiluminescence immunoassay (CLIA) using a 
commercial kit (CLIA kit for Angiotensin II, CCA005Hu, Cloud-Clone Corp.) and expressed as pg/ml. 
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hsCRP assay 
       hsCRP was measured by a commercial kit (Beckman, CA, USA ) with the lowest detection point 
of 0.1 mg/l. 
Statistical Analysis   
       Data were reported as frequency (percentage) or mean ± SD. Between group comparisons 
were performed with the 1-way analysis of variance (continuous variables)  or with the chi-square  
test (proportions). The time course of both ACE and AT1R gene expression were evaluated within 
each group: comparisons were performed by means of Student’s t-test, paired or unpaired as 
necessary. Finally, these 2 parameters in each group of  subjects with obesity were compared  
with respective values in the control group using an unpaired t-test. 
Probability values of P<0.05 were considered significant. All statistical analyses were performed 
using SPSS, version 17.0 for Windows; SPSS Inc., Chicago, IL, USA statistical software.    
 
 RESULTS 
ACE  and AT1R gene expression without Ang II stimulation in control subjects and subjects with 
obesity  with or without low grade inflammation. 
In control subjects,  ACE-mRNA was expressed  on T-lymphocytes, and did not modify without  Ang 
II stimulus in the culture medium during the entire incubation period (24 hours) (Figure 1). 
Similarly, T-cell AT1R gene expression did not change in absence of Ang II addition to the culture 
medium.   
All the subjects with obesity,  both the groups with hsCRP <3 mg/dl  and >3mg/dl, showed a 
significantly higher ACE gene expression (P<0.001)  than that of the control group when fresh-
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isolated lymphocytes were cultured without Ang II stimulation (Figure 1). The same behavior  was 
found for AT1R gene expression in both groups of subjects with obesity when compared with 
controls (Figure 2). 
Serum adiponectin levels in controls and in subjects with obesity 
       Baseline serum adiponectin levels were significantly (P<0.001) higher in control subjects than 
in subjects with obesity. Data are shown in Figure 4. 
 
Effect of Ang II stimulation on T-cell ACE and AT 1-R gene expression in controls and subjects 
with obesity  
        Addition of  0.05 nmol/L Ang II significantly increased  (P<0.05) ACE mRNA levels in control 
subjects at 18 and  24 hours of incubation (Figure 1).  Similarly, T-cell AT1R gene expression  
significantly increased (P<0.005) at the 24th hour when T-lymphocytes were stimulated by Ang II 
(Figure 2). 
       In subjects with obesity with hsCRP <3 mg/dl, Ang II stimulation caused a significant early  
increase in T lymphocyte ACE-mRNA levels at the 6th and 18th hour of incubation (P< 0.005), 
whereas in the group with hsCRP >3 mg/dl the significant increase (P<0.001) was observed later, 
at the 18th hour,  and increased  further at the 24th hour of incubation; the upregulation of ACE-
gene expression was significantly higher in the group of subjects with obesity with  low-grade 
inflammation (Figure 1). In both group of  subjects with obesity Ang II–stimulation caused an 
increase in T-cell AT1R mRNA levels at  the 6th hour (P< 0.05 ) that was  significantly higher than 
the increase observed in controls; in both groups of subjects with obesity AT1R mRNA levels 
further increased at the  18th and 24th hour with a peak level at 18th hour (P < 0.001) (Figure 2).   
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Effect of Ang II stimulation on T-cell IFN-gamma gene expression 
        In control subjects and in subjects with obesity, IFN-gamma gene expression was detectable 
under baseline conditions and did not significantly change during the overall time course when T-
lymphocytes were not stimulated by  Ang II. Conversely, the addition of Ang II was associated with 
a significant increase (P< 0.001) in IFN-gamma mRNA levels at 18 hours, that peaked at 24 hours 
without differences between controls and both groups of subjects with obesity (Figure 3). 
ACE activity in control subjects and subjects with obesity in basal conditions and after Ang II 
stimulation. 
        Table 2 shows the pattern of  ACE activity in the T-cell pellet and supernatant without Ang II 
stimulation in the 3 groups. In control subjects, T-cell pellet ACE activity was detectable at baseline 
and   did not significantly change at 24 hours; in the supernatant, ACE activity was scarcely 
detectable during the 24 hours of incubation. At baseline in both groups of  subjects with obesity, 
pellet ACE enzymatic activity was significantly higher (P<0.001)  than that assayed in controls, with 
higher values in subjects with obesity with hsCRP >3 mg/dl, even if not significantly different in 
respect to subjects with obesity with hsCRP <3 mg/dl. During the 24 hours of  incubation without 
Ang II,  ACE activity did not significantly change  in the pellet, but significantly increased  in the 
supernatant (P< 0.001 vs controls).  After Ang II stimulation  in  all subjects with obesity, ACE 
activity did not significantly change in the pellet, but did significantly increase in the supernatant; 
the increase in the supernatant was higher in subjects with obesity with hsCRP >3 mg/dl (P< 0.001) 
compared with subjects with obesity with hsCRP <3 mg/dl. 
Cell pellet Ang II concentration  in control subjects and subjects with obesity in basal conditions 
and after Ang II stimulation. 
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        Ang II concentration in the pellet of  T-cells of control subjects was significantly lower (P< 
0.001) than that of subjects with obesity throughout the 24 hours of incubation with and without  
stimulus. Subjects with obesity with hsCRP >3 mg/dl  showed a higher Ang II pellet concentration  
than subjects with obesity with hs CRP <3 mg/dl; however, at baseline and at the 24th hour of 
incubation without Ang II stimulus, the difference was not statistically significant. With the 
addition of Ang II, at the 24th hour pellet Ang II concentration was significantly higher (P<0.05) in  
subjects with obesity with hsCRP >3 mg/dl (Table 2) 
 
Ang II plasma concentration in control subjects and subjects with obesity 
        Ang II levels in plasma of control subjects and subjects with obesity did not significantly differ 
among the groups studied (12.5+4.5 pg/ml, 11.6+5.2 pg/ml, 13.1+6.2 pg/ml in controls, subjects 
with obesity with hsCRP <3 and subjects with obesity with hsCRP >3, respectively). 
 
 
DISCUSSION 
        Our data show a selective upregulation of circulating lymphocytic RAS in subjects with 
obesity, independent of low-grade inflammation that amplified the upregulation of T-cell RAS by 
Ang II in subjects with obesity with hsCRP >3 mg/dl. 
        ACE and AT1R gene expression of  T-cells in subjects with obesity was significantly higher than 
in controls and further increased after Ang II stimulation of  T- cells. Subjects with obesity with low 
grade inflammation showed a higher prevalence of metabolic syndrome. The upregulation  of ACE-
gene expression was significantly higher in the group of subjects with obesity with low-grade 
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inflammation and was associated with a significant release of ACE activity in the supernatant of  T- 
cells;  remarkably, the addition of  Ang II stimulus to cultured T-cells caused the almost complete 
release of ACE activity in the medium.             
        Subjects with obesity with hsCRP> 3mg/dl showed a significantly higher (P< 0.05) T- cell  Ang II 
pellet concentration with Ang II stimulation. The increase of Ang II concentration in activated T-
cells could have clinical relevance when occurring within tissues where circulating T-cells are 
known to migrate. The enhanced Ang II release by T-cells could start a dangerous positive loop in 
inflamed tissues and further amplify the activation of the immune response. 6 
Remarkably, our in vitro finding of the marked release of ACE enzymatic activity in the supernatant 
by cultured T-cell from subjects with obesity with low grade inflammation, in vivo could  give rise 
to  a  local increased activation of  other cells endowed with AT1R, such as monocyte and 
macrophage infiltration  in subjects with obesity and other tissues by the de novo synthesized Ang 
II.2 
        It is well-known that obesity predisposes to metabolic disease and that many type 2 diabetes 
patients are obese. Several studies in humans and animals find obesity associated with enhanced 
activity of  both systemic RAS and adipose tissue RAS.10 In particular, AGT synthesis is very 
developed in adipocytes and contributes significantly to the systemic pool. The activity of tissue 
RAS is higher in visceral/central adipose tissue than in subcutaneous tissue and this finding might 
explain the risks related to upper body visceral fat accumulation.16  Many  immediate effects of 
Ang II are mediated via the AT1R through classical G-protein-dependent signaling pathways. 
Stimulation of the AT1R also activates the membrane-bound NAD(P)H oxidase leading to increased 
generation of reactive oxygen species (ROS). The NAD(P)H formed ROS may activate mitochondrial 
KATP channels to additionally burst mitochondrial ROS generation.
17 After its generation, 
intracellular ROS can activate many down-stream molecules, such as mitogen-activated protein 
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kinases, protein tyrosine phosphatases, protein tyrosine kinases, and transcriptional factors, 
which, if chronically activated, will promote inflammation, atherosclerosis, thrombosis, and 
fibrogenesis.18,19,20 
        Low-grade inflammation has been widely associated with atherosclerosis and cardiovascular 
disease. CRP directly binds highly atherogenic oxidized low-density lipoprotein cholesterol (LDL-C) 
and is present within lipid-laden plaques; CRP may facilitate lympho-monocyte adhesion and 
transmigration into the vessel wall, a critical early step in the atherosclerotic process.21 
        In our previous study we demonstrated that there is an increase in circulating T-lymphocyte 
RAS activation in hypertensive patients, related to low-grade inflammation (increased serum 
hsCRP) and BMI. 14 Hypertensive patients with low-grade inflammation presented upregulation of 
lymphocytic RAS and showed the highest left ventricular mass index (LVMI) and renal resistive 
index values, making it possible to hypothesize that in patients with low-grade inflammation  
higher local cardiac and renal Ang II concentration due to T-cell RAS activation could facilitate a 
worse progression of hypertension-related  tissue organ damage. 
        Circulating T-lymphocytes RAS activation in subjects with obesity could be involved in organ 
damage, as seen for hypertensive subjects. It is well-known that adipose tissue (particularly 
visceral adipose tissue) of obese rodents presents a major reserve of CD4+ and CD8+ T-
lymphocytes, compared to lean rodents.22 T-lymphocytes could play an important role also in 
metabolic and vascular complications related to obesity, as they modulate immune response in 
atherogenesis producing Th1 cytokines and promoting classically activated M1 macrophages. 23 
        The low number of subjects investigated, weaken our results, even if  the homogenous  
pattern of lymphocyte RAS in subjects with obesity with or without low  
grade inflammation strongly supports our findings. T-cell RAS activation was studied by the 
measurement of ACE and AT1R gene expression without the dosage of renin, angiotensinogen and 
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AT1R proteins, because ACE and AT1R  are the key  steps of  RAS  activity. Remarkably, ACE and 
AT1R are the target  of  drugs. The lack of a follow-up limits the understanding of potential in vivo 
tissue damage due to RAS lymphocyte-based activation and due to the increased local 
concentration of Ang II shown in vitro. 
        In conclusion, low grade inflammation amplifies angiotensin II activation of upregulated  
circulating T-cell renin angiotensin system in subjects with obesity. In  individuals with obesity the 
enhanced Ang II release by T-cells in the presence of low grade inflammation could start a 
dangerous positive loop in inflamed tissues and further amplify the activation of the immune 
response.  
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Figure Legend 
Figure 1. ACE gene expression in control and subjects with obesity. 
       Abbreviations: Ang II, angiotensin II; hsCRP, high sensitivity C-reactive protein. 
       ° P< 0.001 vs controls (unpaired t-test). 
       *P<0.05 vs without stimulus (paired t-test). 
       # P<0.001 vs without stimulus (paired t-test). 
 
Figure 2. AT1R gene expression in control and subjects with obesity. 
        Abbreviations: Ang II, angiotensin II; hsCRP, high sensitivity C-reactive protein. 
        ° P< 0.05 vs controls. 
        § P< 0.001 vs controls ; *P< 0.005 vs without stimulus. 
        # P< 0.001 vs without stimulus.  
 
Figure 3.   IFNgamma gene expression in control and subjects with obesity. 
       Abbreviations: Ang II, angiotensin II; hsCRP, high sensitivity C-reactive protein. 
       # P< 0.001 vs without stimulus.   
 
Figure 4. Adiponectin serum concentration in control and subjects with obesity. 
       Abbreviations: hsCRP, high sensitivity C-reactive protein. 
       # P< 0.001 vs  controls. 
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